Pro-Bono Ultra-Rare Disease Regulatory Assistance Program Created by MMS for Patient Advocacy Groups With the Greatest Need

Pro-Bono Ultra-Rare Disease Regulatory Assistance Program Created by MMS for Patient Advocacy Groups With the Greatest Need [BUSINESS WIRE] )– MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today the launch of its pro-bono support program aimed at advancing research for ultra-rare diseases. Within this program, MMS will select from patient advocacy groups with demonstrable need and will provide complimentary regulatory assistance.

Read the source article at biospace.com
2021-08-12 04:00:00